<VariationArchive RecordType="classified" VariationID="1173993" VariationName="NM_052845.4(MMAB):c.367del (p.Asp123fs)" VariationType="Deletion" Accession="VCV001173993" Version="6" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2023-12-30" DateCreated="2021-06-26" MostRecentSubmission="2023-12-30">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1163096" VariationID="1173993">
      <GeneList>
        <Gene Symbol="MMAB" FullName="metabolism of cobalamin associated B" GeneID="326625" HGNC_ID="HGNC:19331" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>12q24.11</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="109553715" stop="109573504" display_start="109553715" display_stop="109573504" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="109991519" stop="110011357" display_start="109991519" display_stop="110011357" Strand="-" />
          </Location>
          <OMIM>607568</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_052845.4(MMAB):c.367del (p.Asp123fs)</Name>
      <CanonicalSPDI>NC_000012.12:109561833:CC:C</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>12q24.11</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="109561834" stop="109561834" display_start="109561834" display_stop="109561834" variantLength="1" positionVCF="109561833" referenceAlleleVCF="TC" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="109999639" stop="109999639" display_start="109999639" display_stop="109999639" variantLength="1" positionVCF="109999638" referenceAlleleVCF="TC" alternateAlleleVCF="T" />
      </Location>
      <ProteinChange>D123fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_052845.3" sequenceAccession="NM_052845" sequenceVersion="3" change="c.367delG">
            <Expression>NM_052845.3:c.367delG</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000012.11" sequenceAccession="NC_000012" sequenceVersion="11" change="g.109999640del" Assembly="GRCh37">
            <Expression>NC_000012.11:g.109999640del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000012.12" sequenceAccession="NC_000012" sequenceVersion="12" change="g.109561835del" Assembly="GRCh38">
            <Expression>NC_000012.12:g.109561835del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007096.1" sequenceAccession="NG_007096" sequenceVersion="1" change="g.16664del">
            <Expression>NG_007096.1:g.16664del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_052845.4" sequenceAccession="NM_052845" sequenceVersion="4" change="c.367del" MANESelect="true">
            <Expression>NM_052845.4:c.367del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_443077.1" sequenceAccession="NP_443077" sequenceVersion="1" change="p.Asp123fs">
            <Expression>NP_443077.1:p.Asp123fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_038118.2" sequenceAccession="NR_038118" sequenceVersion="2" change="n.391del">
            <Expression>NR_038118.2:n.391del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1387128853" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_052845.4(MMAB):c.367del (p.Asp123fs) AND Methylmalonic aciduria, cblB type" Accession="RCV001527448" Version="3">
        <ClassifiedConditionList TraitSetID="791">
          <ClassifiedCondition DB="MedGen" ID="C1855102">Methylmalonic aciduria, cblB type</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-11-03" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_052845.4(MMAB):c.367del (p.Asp123fs) AND Methylmalonic acidemia" Accession="RCV003120620" Version="3">
        <ClassifiedConditionList TraitSetID="9017">
          <ClassifiedCondition DB="MedGen" ID="C0268583">Methylmalonic acidemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-01-20" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-01-20" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2021-06-26" MostRecentSubmission="2023-12-30">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">34796408</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="791" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2915" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Methylmalonic acidemia cblB type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Methylmalonic aciduria, cblB type</ElementValue>
                <XRef ID="MONDO:0009614" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Vitamin B12-responsive methylmalonic acidemia type cblB</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">METHYLMALONIC ACIDURIA, VITAMIN B12-RESPONSIVE, DUE TO DEFECT IN SYNTHESIS OF ADENOSYLCOBALAMIN, cblB TYPE</ElementValue>
                <XRef Type="MIM" ID="251110" DB="OMIM" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="9479" />
                <XRef ID="9479" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">For this GeneReview, the term "isolated methylmalonic acidemia" refers to a group of inborn errors of metabolism associated with elevated methylmalonic acid (MMA) concentration in the blood and urine that result from the failure to isomerize (convert) methylmalonyl-coenzyme A (CoA) into succinyl-CoA during propionyl-CoA metabolism in the mitochondrial matrix, without hyperhomocysteinemia or homocystinuria, hypomethioninemia, or variations in other metabolites, such as malonic acid. Isolated MMA is caused by complete or partial deficiency of the enzyme methylmalonyl-CoA mutase (mut0 enzymatic subtype or mut– enzymatic subtype, respectively), a defect in the transport or synthesis of its cofactor, 5-deoxy-adenosyl-cobalamin (cblA, cblB, or cblD-MMA), or deficiency of the enzyme methylmalonyl-CoA epimerase. Prior to the advent of newborn screening, common phenotypes included: Infantile/non-B12-responsive form (mut0 enzymatic subtype, cblB), the most common phenotype, associated with infantile-onset lethargy, tachypnea, hypothermia, vomiting, and dehydration on initiation of protein-containing feeds. Without appropriate treatment, the infantile/non-B12-responsive phenotype could rapidly progress to coma due to hyperammonemic encephalopathy. Partially deficient or B12-responsive phenotypes (mut– enzymatic subtype, cblA, cblB [rare], cblD-MMA), in which symptoms occur in the first few months or years of life and are characterized by feeding problems, failure to thrive, hypotonia, and developmental delay marked by episodes of metabolic decompensation. Methylmalonyl-CoA epimerase deficiency, in which findings range from complete absence of symptoms to severe metabolic acidosis. Affected individuals can also develop ataxia, dysarthria, hypotonia, mild spastic paraparesis, and seizures. In those individuals diagnosed by newborn screening and treated from an early age, there appears to be decreased early mortality, less severe symptoms at diagnosis, favorable short-term neurodevelopmental outcome, and lower incidence of movement disorders and irreversible cerebral damage. However, secondary complications may still occur and can include intellectual disability, tubulointerstitial nephritis with progressive impairment of renal function, "metabolic stroke" (bilateral lacunar infarction of the basal ganglia during acute metabolic decompensation), pancreatitis, growth failure, functional immune impairment, bone marrow failure, optic nerve atrophy, arrhythmias and/or cardiomyopathy (dilated or hypertrophic), liver steatosis/fibrosis/cancer, and renal cancer.</Attribute>
                <XRef ID="NBK1231" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301409</ID>
                <ID Source="BookShelf">NBK1231</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Elevated%20C3%20Acylcarnitine%20PA%20and%20MA.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Elevated C3 Acylcarnitine, Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA), 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C3-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Propionic and Methylmalonic Acidemia: C3 Elevated, 2022</CitationText>
              </Citation>
              <XRef ID="28" DB="Orphanet" />
              <XRef ID="79311" DB="Orphanet" />
              <XRef ID="C1855102" DB="MedGen" />
              <XRef ID="MONDO:0009614" DB="MONDO" />
              <XRef Type="MIM" ID="251110" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9017" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6374" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Isolated Methylmalonic Acidemia</ElementValue>
                <XRef ID="C537358" DB="MeSH" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Methylmalonic acidemia</ElementValue>
                <XRef ID="Methylmalonic+acidemia/4713" DB="Genetic Alliance" />
                <XRef ID="HP:0002912" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0002012" DB="MONDO" />
                <XRef ID="42393006" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MMA</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7033" />
                <XRef ID="7033" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">For this GeneReview, the term "isolated methylmalonic acidemia" refers to a group of inborn errors of metabolism associated with elevated methylmalonic acid (MMA) concentration in the blood and urine that result from the failure to isomerize (convert) methylmalonyl-coenzyme A (CoA) into succinyl-CoA during propionyl-CoA metabolism in the mitochondrial matrix, without hyperhomocysteinemia or homocystinuria, hypomethioninemia, or variations in other metabolites, such as malonic acid. Isolated MMA is caused by complete or partial deficiency of the enzyme methylmalonyl-CoA mutase (mut0 enzymatic subtype or mut– enzymatic subtype, respectively), a defect in the transport or synthesis of its cofactor, 5-deoxy-adenosyl-cobalamin (cblA, cblB, or cblD-MMA), or deficiency of the enzyme methylmalonyl-CoA epimerase. Prior to the advent of newborn screening, common phenotypes included: Infantile/non-B12-responsive form (mut0 enzymatic subtype, cblB), the most common phenotype, associated with infantile-onset lethargy, tachypnea, hypothermia, vomiting, and dehydration on initiation of protein-containing feeds. Without appropriate treatment, the infantile/non-B12-responsive phenotype could rapidly progress to coma due to hyperammonemic encephalopathy. Partially deficient or B12-responsive phenotypes (mut– enzymatic subtype, cblA, cblB [rare], cblD-MMA), in which symptoms occur in the first few months or years of life and are characterized by feeding problems, failure to thrive, hypotonia, and developmental delay marked by episodes of metabolic decompensation. Methylmalonyl-CoA epimerase deficiency, in which findings range from complete absence of symptoms to severe metabolic acidosis. Affected individuals can also develop ataxia, dysarthria, hypotonia, mild spastic paraparesis, and seizures. In those individuals diagnosed by newborn screening and treated from an early age, there appears to be decreased early mortality, less severe symptoms at diagnosis, favorable short-term neurodevelopmental outcome, and lower incidence of movement disorders and irreversible cerebral damage. However, secondary complications may still occur and can include intellectual disability, tubulointerstitial nephritis with progressive impairment of renal function, "metabolic stroke" (bilateral lacunar infarction of the basal ganglia during acute metabolic decompensation), pancreatitis, growth failure, functional immune impairment, bone marrow failure, optic nerve atrophy, arrhythmias and/or cardiomyopathy (dilated or hypertrophic), liver steatosis/fibrosis/cancer, and renal cancer.</Attribute>
                <XRef ID="NBK1231" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301409</ID>
                <ID Source="BookShelf">NBK1231</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Elevated%20C3%20Acylcarnitine%20PA%20and%20MA.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Elevated C3 Acylcarnitine, Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA), 2022</CitationText>
              </Citation>
              <XRef ID="C0268583" DB="MedGen" />
              <XRef ID="C537358" DB="MeSH" />
              <XRef ID="MONDO:0002012" DB="MONDO" />
              <XRef Type="primary" ID="HP:0002912" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0003123" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0008295" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3425712" SubmissionDate="2021-06-21" DateLastUpdated="2021-06-26" DateCreated="2021-06-26">
        <ClinVarSubmissionID localKey="NM_052845.4:c.367del|MedGen:C1855102" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV001738458" DateUpdated="2021-06-26" DateCreated="2021-06-26" Type="SCV" Version="1" SubmitterName="Baumgartner lab, University Children's Hospital Zurich" OrgID="508145" OrganizationCategory="clinic" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-06-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation Type="general">
            <ID Source="PubMed">34796408</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_052845.4:c.367del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1855102" Type="CUI" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">34796408</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">34796408</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB9886015</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7081849" SubmissionDate="2023-02-06" DateLastUpdated="2023-11-11" DateCreated="2023-02-13">
        <ClinVarSubmissionID localKey="NM_052845.3:c.367delG|MedGen:C0268583" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003801230" DateUpdated="2023-11-11" DateCreated="2023-02-13" Type="SCV" Version="2" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-01-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">34796408</ID>
          </Citation>
          <Comment>Variant summary: MMAB c.367delG (p.Asp123ThrfsX18) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 4.2e-06 in 237140 control chromosomes. c.367delG has been reported in the literature in at-least one individual affected with Methylmalonic Acidemia (PMID:34796408). One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MMAB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_052845.3:c.367delG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0268583" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12766635</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7846444" SubmissionDate="2023-12-07" DateLastUpdated="2023-12-30" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_052845.4:c.367del|OMIM:251110" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004193154" DateUpdated="2023-12-30" DateCreated="2023-12-30" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-11-03">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_052845.4:c.367del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="251110" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7081849" TraitType="Disease" MappingType="XRef" MappingValue="C0268583" MappingRef="MedGen">
        <MedGen CUI="C0268583" Name="Methylmalonic acidemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3425712" TraitType="Disease" MappingType="XRef" MappingValue="C1855102" MappingRef="MedGen">
        <MedGen CUI="C1855102" Name="Methylmalonic aciduria, cblB type" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7846444" TraitType="Disease" MappingType="XRef" MappingValue="251110" MappingRef="OMIM">
        <MedGen CUI="C1855102" Name="Methylmalonic aciduria, cblB type" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

